Haoxi Health Technology (HAO) Cash & Equivalents (2023 - 2025)

Haoxi Health Technology's Cash & Equivalents history runs 3 years deep, the most recent figure standing at $6.8 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 25.23% year-over-year to $6.8 million in Q4 2025; TTM through Dec 2025 was $6.8 million, a 25.23% decrease from a year earlier, with the FY2025 full-year figure at $8.6 million, up 29.49% from the prior year.
• Cash & Equivalents retreated to $6.8 million in Q4 2025 per HAO's latest filing, from $8.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $9.1 million in Q4 2024 and bottomed at $1.2 million in Q2 2023.
• The 3-year median for Cash & Equivalents is $6.8 million (2025), against an average of $6.5 million.
• Across the five-year window, Cash & Equivalents soared 453.17% in 2024 and dropped 25.23% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $1.2 million in 2023, then surged by 656.02% to $9.1 million in 2024, then dropped by 25.23% to $6.8 million in 2025.
• Per Business Quant, the three latest HAO Cash & Equivalents figures stand at $6.8 million (Q4 2025), $8.6 million (Q2 2025), and $9.1 million (Q4 2024).